The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Open accessAbstract
BACKGROUNDLipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis.There are no approved pharmacologic therapies to lower lipoprotein(a) levels. METHODSWe conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter).Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L Rx , referred to here as APO(a)-L Rx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months.The lipoprotein(a) level was measured with an isoform-independent assay.The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses). RESULTSThe median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter.Administration of APO(a)-L Rx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001).There were no significant differences between any APO(a)-L Rx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms.The most common adverse events were injection-site reactions.CONCLUSIONS APO(a)-L Rx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“At the same time, pelacarsen was well tolerated. Only injection site reactions were more frequently observed in the treatment group.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistently, in a randomized, double-blind, placebo-controlled phase 2 trial of 286 patients with elevated Lp(a) levels and established CVD, pelacarsen reduced Lp(a) in a dose-dependent manner by up to − 80% from baseline [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
The cited source says what the claim attributes to it.
In the citing paper
“Lp(a) has been identified as an independent risk marker for CVD as it exerts pro-atherogenic, pro-inflammatory, and pro-thrombotic effects which may play a critical role in the pathogenesis of atherosclerosis [182].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [182]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Self-citationCrooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationvan der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706
Self-citationLipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,001
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 37
Rogers, M. A., Atkins, S. K., Zheng, K. H., Singh, S. A., Chelvanambi, S., Pham, T., Kuraoka, S., Stroes, E. S. G., Aikawa, M., & Aïkawa, E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.778919 · Cited by 36
Self-citationImpact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy
Tomoi, Y., Takahara, M., Soga, Y., Kodama, K., Imada, K., Hiramori, S., & Andò, K. (2022) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2022.05.050 · Cited by 35
Recent Advances in Gene Therapy for Familial Hypercholesterolemia: An Update Review
Fu, Q., Hu, L., Shen, T., Yang, R., & Jiang, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226773 · Cited by 41
The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis
Sud, K., Narula, N., Aïkawa, E., Arbustini, E., Pîbarot, P., Merlini, G., Rosenson, R. S., Seshan, S. V., Argulian, E., Ahmadi, A. A., et al. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00818-2 · Cited by 36
Self-citationWard, N. C., Watts, G. F., Bishop, W., Colquhoun, D., Hamilton-Craig, C. R., Hare, D. L., Kangaharan, N., Kostner, K., Kritharides, L., O’Brien, R. C., et al. (2023) · Heart Lung and Circulation · doi:10.1016/j.hlc.2022.11.015 · Cited by 37
Therapeutic Potential of Lipoprotein(a) Inhibitors
Nicholls, S. J. (2024) · Drugs · doi:10.1007/s40265-024-02046-z · Cited by 39
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention
Katsanos, A. H., & Hart, R. G. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2494 · Cited by 34
Lipoprotein (a): Recent Updates on a Unique Lipoprotein
Saeed, A., Kinoush, S., & Virani, S. S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00940-5 · Cited by 35
Guertin, J., Kaiser, Y., Manikpurage, H. D., Perrot, N., Bourgeois, R., Couture, C., Wareham, N. J., Bossé, Y., Pîbarot, P., Stroes, E. S. G., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003271 · Cited by 36
Self-citationLipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis
Lee, C., Liao, C., Meng, S., Wu, W., Chiang, J., & Wu, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080985 · Cited by 39
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Uceta, R. E., Guzman, E., & Rallidis, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713622 · Cited by 36
The Effect of Bariatric Surgery on Circulating Levels of Lipoprotein (a): A Meta‐analysis
Jamialahmadi, T., Reiner, Ž., Alidadi, M., Kroh, M., Almahmeed, W. A., Ruscica, M., Sirtori, C. R., Rizzo, M., Santos, R. D., & Sahebkar, A. (2022) · BioMed Research International · doi:10.1155/2022/8435133 · Cited by 33
Langsted, A., & Nordestgaard, B. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000681 · Cited by 33
Self-citationLipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 32
Self-citationA Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent
Hardy, J., Niman, S., Goldfaden, R. F., Ashchi, M., Bisharat, M. B., Huston, J., Hartmann, H., & Choksi, R. R. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00499-1 · Cited by 35
Youssef, A., Clark, J. R., Marcovina, S. M., Boffa, M. B., & Koschinsky, M. L. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317335 · Cited by 34
Understanding the ins and outs of lipoprotein (a) metabolism
Boffa, M. B., & Koschinsky, M. L. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000823 · Cited by 34
Gene editing for dyslipidemias: New tools to “cut” lipids
Stankov, S. G., & Cuchel, M. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.010 · Cited by 34
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 33
Self-citationLipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Greco, M. F., Sirtori, C. R., Corsini, A., Владиславович, Е. М., Sampietro, T., & Ruscica, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072103 · Cited by 33
Cao, Y., Zhang, H., Jin, J., Liu, H., Zhang, Y., Zhang, M., Gao, Y., Guo, Y., Wu, N., Zhu, C., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/a-1340-2109 · Cited by 32
RNA Silencing in the Management of Dyslipidemias
Henney, N. C., Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00968-7 · Cited by 32
Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals
Lee, H., Park, K. S., Jeon, Y., Park, E. J., Park, S., Ann, S. H., Kim, Y., Lee, Y. J., Choi, S. H., & Park, G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.027 · Cited by 32
The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target
Koschinsky, M. L., & Kronenberg, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.017 · Cited by 32
Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis
Halacoglu, J., & Shea, L. A. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-09964-9 · Cited by 33
Pediatric Dyslipidemia—Beyond Familial Hypercholesterolemia
Lazarte, J., & Hegele, R. A. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.03.020 · Cited by 32
Wilson, D. P., Koschinsky, M. L., & Moriarty, P. M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000624 · Cited by 31
Self-citationJiang, Q., Qin, D., Yang, L., Lin, Y., Zhai, L., Zhang, Y., Yang, G., Wang, K., Tong, D., Li, X., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.011 · Cited by 33
Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
Handhle, A., Viljoen, A., & Wierzbicki, A. S. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266244 · Cited by 31
Chakraborty, A., Pang, J., Chan, D. C., Ellis, K. L., Hooper, A. J., Bell, D. A., Burnett, J. R., Moses, E. K., & Watts, G. F. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.004 · Cited by 31
Yuan, D., Wang, P., Jia, S., Zhang, C., Zhu, P., Jiang, L., Liu, R., Xu, J., Tang, X., Song, Y., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.10.013 · Cited by 31
de Boer, L. M., Hutten, B. A., Zwinderman, A. H., & Wiegman, A. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac660 · Cited by 31
Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events
Guédon, A. F., de Fréminville, J.-B., Mirault, T., Mohamedi, N., Rance, B., Fournier, N., Paul, J., Messas, E., & Goudot, G. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.45720 · Cited by 32
European guidelines for the treatment of dyslipidaemias: New concepts and future challenges
Pirillo, A., Casula, M., & Catapano, A. L. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106936 · Cited by 38
Raitakari, O. T., Kivelä, A. M., Pahkala, K., Rovio, S., Mykkänen, J., Ahola‐Olli, A., Loo, B.-M., Lyytikäinen, L., Lehtimäki, T. J., Kähönen, M. A. P., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.07.009 · Cited by 30
The MOE Modification of RNA: Origins and Widescale Impact on the Oligonucleotide Therapeutics Field
Hill, A. C., & Hall, J. (2023) · Helvetica Chimica Acta · doi:10.1002/hlca.202200169 · Cited by 31
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 31
Self-citationAssociation of Lipoprotein(a) With Major Adverse Cardiovascular Events Across hs-CRP
Alebna, P. L., Han, C. Y., Ambrosio, M., Kong, G., Cyrus, J. W. W., Harley, K., Kang, L., Small, A., Chevli, P. A., Bhatia, H. S., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101409 · Cited by 30
Self-citationShould Lipoprotein(a) be Measured in Youth?
Kohn, B., Ashraf, A. P., & Wilson, D. P. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.08.042 · Cited by 30
Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation
Fatica, E. M., Meeusen, J. W., Vasile, V. C., Jaffe, A. S., & Donato, L. J. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.09.007 · Cited by 31
Cis -epistasis at the LPA locus and risk of cardiovascular diseases
Zeng, L., Moser, S., Mirza‐Schreiber, N., Lamina, C., Coassin, S., Nelson, C. P., Annilo, T., Franzén, O., Kleber, M. E., Mack, S. R., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab136 · Cited by 34
Self-citationDyslipidemia in Patients with Kidney Disease
Thobani, A., & Jacobson, T. A. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.008 · Cited by 30
Current RNA strategies in treating cardiovascular diseases
Chia, S. P. S., Pang, J. K. S., & Soh, B.-S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.028 · Cited by 32
Zhu, L., Fang, Y., Gao, B., Jin, X., Zheng, J., He, Y., & Huang, J. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02932-y · Cited by 30
Loh, W. J., Chan, D. C., Mata, P., & Watts, G. F. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.905941 · Cited by 29
Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications
Koutsogianni, A. D., Liamis, G. L., Liberopoulos, E. N., Adamidis, P. S., & Florentin, M. (2023) · Pharmaceuticals · doi:10.3390/ph16050750 · Cited by 29
Karwatowska-Prokopczuk, E., Clouet-Foraison, N., Xia, S., Viney, N. J., Witztum, J. L., Marcovina, S. M., & Tsimikas, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.036 · Cited by 27
Self-citationAdvances in Extracellular Matrix-Associated Diagnostics and Therapeutics
Karsdal, M. A., Cox, T. R., Parker, A. L., Willumsen, N., Sand, J. M. B., Jenkins, G. R., Hansen, H. H., Oldenburger, A., Geillinger‐Kästle, K. E., Larsen, A. T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061856 · Cited by 29
Fischer, L. T., Hochfellner, D. A., Knoll, L., Pöttler, T., Mader, J. K., & Aberer, F. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01283-w · Cited by 27
Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Hu, J., Lei, H. C., Liu, L., & Xu, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812368 · Cited by 28
Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus
Kostner, K., & Kostner, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073584 · Cited by 27
RNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 29
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing Therapies
Chan, D. C., & Watts, G. F. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.07.008 · Cited by 30
Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option
Maloberti, A., Fabbri, S., Colombo, V., Gualini, E., Monticelli, M., Daus, F., Busti, A., Galasso, M., Censi, L. D., Algeri, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010170 · Cited by 26
Duan, Y., Zhao, D. H., Sun, J., Liu, J., Wang, M., Hao, Y., Li, J., Liu, T., Xiao, L., Hao, Y., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.042323 · Cited by 29
The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
Vavuranakis, M., Jones, S. R., Cardoso, R. N., Gerstenblith, G., & Leucker, T. M. (2020) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2020.09.016 · Cited by 26
Novel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 26
Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis
Bhatia, H. S., Ma, G. S., Taleb, A., Wilkinson, M. J., Kahn, A. M., Cotter, B. R., Yeang, C., DeMaria, A. N., Patel, M. P., Mahmud, E., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.022 · Cited by 26
Self-citationAdvancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj, A., & Cuchel, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17065 · Cited by 28
Lipoprotein(a)—60 Years Later—What Do We Know?
Pasławska, A., & Tomasik, P. (2023) · Cells · doi:10.3390/cells12202472 · Cited by 31
Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides
Løvendorf, M. B., Holm, A., Petri, A., Thrue, C. A., Uchida, S., Venø, M. T., & Kauppinen, S. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0040 · Cited by 26
Lipoprotein(a) and panvascular disease
Xu, R., Wang, Z., Dong, J., Yu, M., & Zhou, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02600-y · Cited by 29
Recent Updates of Lipoprotein(a) and Cardiovascular Disease
Liu, T., Yoon, W.-S., & Lee, S. R. (2021) · Chonnam Medical Journal · doi:10.4068/cmj.2021.57.1.36 · Cited by 25
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 25
Cui, K., Yin, D., Zhu, C., Song, W., Wang, H., Jia, L., Zhang, R., Wang, H., Cai, Z., Feng, L., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023578 · Cited by 25
Stătescu, C., Anghel, L., Benchea, L.-C., Tudurachi, B.-S., Leonte, A., Zăvoi, A., Zota, I. M., Prisacariu, C., Radu, R., Șerban, I.-L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065927 · Cited by 25
Treatment of Lp(a): Is It the Future or Are We Ready Today?
Tselepis, A. D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01141-y · Cited by 25
Gogate, A., Belcourt, J., Shah, M., Wang, A., Frankel, A., Kolmel, H., Chalon, M., Stephen, P., Kolli, A., Tawfik, S. M., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000815 · Cited by 27
Dyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 26
Bhatia, H. S., Rikhi, R. R., Allen, T. S., Yeang, C., Guan, W., Garg, P. K., Tsai, M. Y., Criqui, M. H., Shapiro, M. D., & Tsimikas, S. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117217 · Cited by 25
Self-citationDyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives
Karantas, I. D., Okur, M. E., Okur, N. Ü., & Siafaka, P. I. (2020) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530320666200810144004 · Cited by 25
Ho, J. H., Adam, S., Liu, Y., Azmi, S., Dhage, S. S., Syed, A. A., Ammori, B. J., Donn, R. P., Heald, A. H., Gibson, M., et al. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.12.002 · Cited by 24
Self-citationElevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly
Tsimikas, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab251 · Cited by 24
Self-citationLipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy
Iannuzzo, G., Tripaldella, M., Mallardo, V., Morgillo, M., Vitelli, N., Iannuzzi, A., Aliberti, E., Giallauria, F., Tramontano, A. L., Carluccio, R., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9070838 · Cited by 29
Littmann, K., Hagström, E., Häbel, H., Bottai, M., Eriksson, M., Parini, P., & Brinck, J. W. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab016 · Cited by 24
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)
Kim, K. A., & Park, H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.37 · Cited by 23
Li, S., Xu, Z., Wang, Y., Chen, L., Wang, X., Zhou, Y., Lei, D., Zang, G., & Wang, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.016 · Cited by 25
Chiesa, G., Zenti, M. G., Baragetti, A., Barbagallo, C. M., Borghi, C., Colivicchi, F., Maggioni, A. P., Noto, D., Pirro, M., Rivellese, A. A., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.019 · Cited by 24
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
Szarek, M. J., Bhatt, D. L., Miller, M. J., Brinton, E. A., Jacobson, T. A., Tardif, J., Ballantyne, C. M., Mason, R. P., Ketchum, S. B., Pineda, A. L., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.016 · Cited by 24
Self-citationBen‐Nun, D., Buja, L. M., & Fuentes, F. J. (2020) · Cardiovascular Pathology · doi:10.1016/j.carpath.2020.107243 · Cited by 26
Dyslipidemia and aortic valve disease
Mata, P., Rodrigo Alonso, K., de Isla, L. P., & Badimón, L. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000794 · Cited by 23
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 23
Lipoprotein(a) association with residual risk: what has inflammation got to do with it?
Farukhi, Z. M., & Mora, S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae045 · Cited by 22
Clarke, R., Wright, N., Lin, K., Yu, C., Walters, R. G., Lv, J., Hill, M., Kartsonaki, C., Millwood, I. Y., Bennett, D., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072086 · Cited by 28
Residual lipid risk in atherosclerotic cardiovascular disease
Nordestgaard, B. G., & Hegele, R. A. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag087 · Cited by 29
Self-citationUnravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21
Puri, R., Mehta, V., Duell, P. B., Iyengar, S. S., Yusuf, J., Dalal, J., Narasingan, S. N., Kalra, D. K., Kapoor, A., Pradhan, A. K., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.03.008 · Cited by 22
Silverio, A., Cancro, F. P., Esposito, L., Bellino, M., D’Elia, D., Verdoia, M., Vassallo, M. G., Ciccarelli, M., Vecchione, C., Galasso, G., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062161 · Cited by 29
Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment
Wulff, A. B., Nordestgaard, B. G., & Langsted, A. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01192-9 · Cited by 23
Self-citationTargeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol
Newman, C. B., & Tobert, J. A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac708 · Cited by 20
Risk Factors for Cardiovascular and Metabolic Disease: Integrating Traditional and Novel Paradigms
Wang, Z., Chen, S., Xu, S., & Weng, J. (2025) · iNew Medicine · doi:10.1002/inm3.70000 · Cited by 24
Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia
Pokrovsky, S. N., Afanasieva, O. I., & Владиславович, Е. М. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00886-0 · Cited by 21
Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations
Dron, J. S., Wang, M., Patel, A. P., Kartoun, U., Ng, K., Hegele, R. A., & Khera, A. V. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003182 · Cited by 21
New and Emerging lipid-lowering Therapy
Backes, J. M., & Hilleman, D. E. (2021) · Future Cardiology · doi:10.2217/fca-2020-0217 · Cited by 21
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 21
Oxidized phospholipids and lipoprotein(a): An update
Koutsogianni, A. D., Liberopoulos, E. N., Tellis, K., & Tselepis, A. D. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13710 · Cited by 21
Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
Parham, J. S., & Goldberg, A. C. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.11.011 · Cited by 22
Metadata
- Authors
- Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., Xia, S., Guerriero, J., Viney, N. J., O’Dea, L., & Witztum, J. L.
- Affiliations
- University of Cologne (DE)
- From the Divisions of Cardiovascular Medicine (S.T.) and Endocrinology and Metabolism (J.L.W.), University of California, San Diego, La Jolla, and Ionis Pharmaceuticals, Carlsbad (S.T., S.X., N.J.V.) — both in California; Akcea Therapeutics, Boston (E.K.-P., J.G., L.O.); Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Cologne, Germany (I.G.-B.); Montreal Heart Institute, Université de Montréal, Montreal (J.-C.T.); Excel Medical Clinical Trials, Boca Raton, FL ...
- Oregon Health & Science University (US)
- University of Copenhagen (DK)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-16
- Volume
- 382
- Issue
- 3
- Pages
- 244-255
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2997944188
- Semantic Scholar
- 725c405ccc1ec3726f9ba922da158107891d134f
- Cited by
- 1,094
- References
- 28
- Citations by year
- 2026: 204 · 2025: 176 · 2024: 156 · 2023: 149 · 2022: 159 · 2021: 153 · 2020: 96
- FWCI
- 127.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Akcea Therapeutics
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), antisense oligonucleotides, cardiovascular disease, injection site reactions, genetic risk factors
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Cardiovascular Diseases, Cholesterol, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Oligonucleotides, Risk Factors, Least-Squares Analysis, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
